PowerShow.com
  • Help
  • Preferences
  • Sign up
  • Log in
Advanced
Free template

Sabcs PowerPoint PPT Presentations

Grid List
All Time
All TimeAdded TodayAdded This WeekAdded This Month
Show:
Recommended
RecommendedRelevanceLatestHighest RatedMost Viewed
Sort by:
Featured Presentations
Search Results
SABCS 2011 BOLERO-2 Updated Results PowerPoint PPT Presentation
SABCS 2011 BOLERO-2 Updated Results - SABCS 2011 BOLERO-2 Updated Results Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial
SABCS 2011 BOLERO-2 Updated Results Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial
| PowerPoint PPT presentation | free to download
2013 SABCS Review PowerPoint PPT Presentation
2013 SABCS Review - Title: PowerPoint Presentation Author: Tricia Perea Last modified by: Allison Brown Created Date: 2/7/2013 8:38:08 PM Document presentation format
Title: PowerPoint Presentation Author: Tricia Perea Last modified by: Allison Brown Created Date: 2/7/2013 8:38:08 PM Document presentation format
| PowerPoint PPT presentation | free to view
SABCS 2011 CLEOPATRA PowerPoint PPT Presentation
SABCS 2011 CLEOPATRA - SABCS 2011 CLEOPATRA A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab ...
SABCS 2011 CLEOPATRA A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab ...
| PowerPoint PPT presentation | free to download
Radiation Therapy Update: SABCS 2005 PowerPoint PPT Presentation
Radiation Therapy Update: SABCS 2005 - ... Presentation PowerPoint Presentation PowerPoint Presentation PowerPoint Presentation Breast conservation without radiotherapy Breast conservation without ...
... Presentation PowerPoint Presentation PowerPoint Presentation PowerPoint Presentation Breast conservation without radiotherapy Breast conservation without ...
| PowerPoint PPT presentation | free to view
A critique of SABCs political coverage. PowerPoint PPT Presentation
A critique of SABCs political coverage. - Opportunities that the current political climate offers developmental journalism ... Not restricting access to news sources. ... a plurality of views and news. ...
Opportunities that the current political climate offers developmental journalism ... Not restricting access to news sources. ... a plurality of views and news. ...
| PowerPoint PPT presentation | free to download
A Report from SABCS Up-to-Date Review of the Treatment of Advanced Breast Cancer PowerPoint PPT Presentation
A Report from SABCS Up-to-Date Review of the Treatment of Advanced Breast Cancer - Title: HER Education Network Author: brohling Last modified by: Administrator Created Date: 7/11/2003 3:47:23 PM Document presentation format: On-screen Show
Title: HER Education Network Author: brohling Last modified by: Administrator Created Date: 7/11/2003 3:47:23 PM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to download
SABCs Funding Model Options for the Future PowerPoint PPT Presentation
SABCs Funding Model Options for the Future - 1. SABC's Funding Model Options for the Future. Justine Limpitlaw. Media ... controversial, devil's advocate, puts the cat among the pigeons, stir debate etc ...
1. SABC's Funding Model Options for the Future. Justine Limpitlaw. Media ... controversial, devil's advocate, puts the cat among the pigeons, stir debate etc ...
| PowerPoint PPT presentation | free to view
A Report from SABCS Up-to-Date Review of the Treatment of Early Breast Cancer PowerPoint PPT Presentation
A Report from SABCS Up-to-Date Review of the Treatment of Early Breast Cancer - A Report from SABCS Up-to-Date Review of the Treatment of Early Breast Cancer Maura N. Dickler, MD Assistant Attending Physician Breast Cancer Medicine Service
A Report from SABCS Up-to-Date Review of the Treatment of Early Breast Cancer Maura N. Dickler, MD Assistant Attending Physician Breast Cancer Medicine Service
| PowerPoint PPT presentation | free to download
The SABCs legal structure the benefits disadvantages of a national versus a regional structure PowerPoint PPT Presentation
The SABCs legal structure the benefits disadvantages of a national versus a regional structure - ... within the governance itself, politics will find a way to ... Presidential appointment: 1. Ministerial appointment (Department of Communications): 1 ...
... within the governance itself, politics will find a way to ... Presidential appointment: 1. Ministerial appointment (Department of Communications): 1 ...
| PowerPoint PPT presentation | free to view
CALGB 40603 (1) PowerPoint PPT Presentation
CALGB 40603 (1) - Title: SABCS 2013 Author: La Lettre du Canc rologue Last modified by: Congres01 Created Date: 12/3/2013 12:11:17 PM Document presentation format
Title: SABCS 2013 Author: La Lettre du Canc rologue Last modified by: Congres01 Created Date: 12/3/2013 12:11:17 PM Document presentation format
| PowerPoint PPT presentation | free to download
La Lettre du Canc PowerPoint PPT Presentation
La Lettre du Canc - Title: Zoom SABCS 2010 Author: La Lettre du Canc rologue Last modified by: Charles DUFRENE Created Date: 10/12/2010 10:52:17 AM Document presentation format
Title: Zoom SABCS 2010 Author: La Lettre du Canc rologue Last modified by: Charles DUFRENE Created Date: 10/12/2010 10:52:17 AM Document presentation format
| PowerPoint PPT presentation | free to download
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer PowerPoint PPT Presentation
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer - Baselga J et al. SABCS 2009;Abstract 45. Introduction Phase III trial of capecitabine (CAP) combined with anti-VEGF agent bevacizumab demonstrated an improved ...
Baselga J et al. SABCS 2009;Abstract 45. Introduction Phase III trial of capecitabine (CAP) combined with anti-VEGF agent bevacizumab demonstrated an improved ...
| PowerPoint PPT presentation | free to download
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy PowerPoint PPT Presentation
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy - Gnant M et al. Proc SABCS 2010;Abstract P5-11-02. Gnant M et al. Proc SABCS 2010;Abstract P5-11-02. Endpoints Primary: Disease-free survival (local recurrence ...
Gnant M et al. Proc SABCS 2010;Abstract P5-11-02. Gnant M et al. Proc SABCS 2010;Abstract P5-11-02. Endpoints Primary: Disease-free survival (local recurrence ...
| PowerPoint PPT presentation | free to download
Essai BIG 1-98 PowerPoint PPT Presentation
Essai BIG 1-98 - Title: Zoom SABCS 2012 Author: La Lettre du Canc rologue Last modified by: Pilar Created Date: 12/6/2012 1:59:58 AM Document presentation format
Title: Zoom SABCS 2012 Author: La Lettre du Canc rologue Last modified by: Pilar Created Date: 12/6/2012 1:59:58 AM Document presentation format
| PowerPoint PPT presentation | free to download
Locally advanced and metastatic disease PowerPoint PPT Presentation
Locally advanced and metastatic disease - Study 301: eribulin vs capecitabine trial design * * 2 for advanced disease Kaufman PA et al. SABCS 2012 S6-6 Stratification: - geographic region ...
Study 301: eribulin vs capecitabine trial design * * 2 for advanced disease Kaufman PA et al. SABCS 2012 S6-6 Stratification: - geographic region ...
| PowerPoint PPT presentation | free to view
Time to Recurrence Hormone Receptorpositive Patients PowerPoint PPT Presentation
Time to Recurrence Hormone Receptorpositive Patients - Tamoxifen (T) Anastrozole (A) Adapted from Forbes J. SABCS 2007. ... Tamoxifen (T) Anastrozole (A) Time since randomization (years) Annual fracture episode rates ...
Tamoxifen (T) Anastrozole (A) Adapted from Forbes J. SABCS 2007. ... Tamoxifen (T) Anastrozole (A) Time since randomization (years) Annual fracture episode rates ...
| PowerPoint PPT presentation | free to view
Cetuximab   Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial PowerPoint PPT Presentation
Cetuximab Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial - Baselga J et al. Proc SABCS 2010;Abstract PD01-01. Cetuximab/cisplatin (n = 115) Cetuximab 400 mg/m2 initial 250 mg/m2 weekly Cisplatin 75 mg/m2 d1 q3wk up to 6 ...
Baselga J et al. Proc SABCS 2010;Abstract PD01-01. Cetuximab/cisplatin (n = 115) Cetuximab 400 mg/m2 initial 250 mg/m2 weekly Cisplatin 75 mg/m2 d1 q3wk up to 6 ...
| PowerPoint PPT presentation | free to download
First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer PowerPoint PPT Presentation
First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer - ... (months) 37.8 38.2 1.00 (0.76, 1.32) p = 1.00 1Programmatically derived to RECIST criteria Source: Bergh J et al. SABCS 2009;Abstract 23. Pre-specified Adverse ...
... (months) 37.8 38.2 1.00 (0.76, 1.32) p = 1.00 1Programmatically derived to RECIST criteria Source: Bergh J et al. SABCS 2009;Abstract 23. Pre-specified Adverse ...
| PowerPoint PPT presentation | free to download
Une  PowerPoint PPT Presentation
Une - Une tude de phase II d association du lapatinib et du paclitaxel en traitement n oadjuvant chez des patientes avec un cancer du sein inflammatoire
Une tude de phase II d association du lapatinib et du paclitaxel en traitement n oadjuvant chez des patientes avec un cancer du sein inflammatoire
| PowerPoint PPT presentation | free to download
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial PowerPoint PPT Presentation
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial - Title: Main Title Slide Always use Title Case on Slide Titles Author: Fernando G Rendina Last modified by: Albert Rosado Created Date: 12/17/2009 7:27:13 PM
Title: Main Title Slide Always use Title Case on Slide Titles Author: Fernando G Rendina Last modified by: Albert Rosado Created Date: 12/17/2009 7:27:13 PM
| PowerPoint PPT presentation | free to download
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg PowerPoint PPT Presentation
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg - Title: Research To Practice Created Date: 12/21/2012 6:13:07 PM Document presentation format: On-screen Show (4:3) Other titles: Arial MS P Verdana ...
Title: Research To Practice Created Date: 12/21/2012 6:13:07 PM Document presentation format: On-screen Show (4:3) Other titles: Arial MS P Verdana ...
| PowerPoint PPT presentation | free to download
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831 PowerPoint PPT Presentation
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831 - Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831
| PowerPoint PPT presentation | free to download
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer (PERUSE) PowerPoint PPT Presentation
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer (PERUSE) - Title: Research To Practice Created Date: 12/21/2012 6:13:07 PM Document presentation format: On-screen Show (4:3) Other titles: Arial MS P Verdana ...
Title: Research To Practice Created Date: 12/21/2012 6:13:07 PM Document presentation format: On-screen Show (4:3) Other titles: Arial MS P Verdana ...
| PowerPoint PPT presentation | free to download
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression PowerPoint PPT Presentation
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression - Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression
| PowerPoint PPT presentation | free to download
An%20Interactive%20Webcast%20Featuring%20Discussion%20of%20Key%20Presentations%20and%20Posters%20from%20the%202011%20San%20Antonio%20Breast%20Cancer%20Symposium PowerPoint PPT Presentation
An%20Interactive%20Webcast%20Featuring%20Discussion%20of%20Key%20Presentations%20and%20Posters%20from%20the%202011%20San%20Antonio%20Breast%20Cancer%20Symposium - An Interactive Webcast Featuring Discussion of Key Presentations and Posters from the 2011 San Antonio ... and Fulvestrant as First-Line ... Trial to Evaluate ...
An Interactive Webcast Featuring Discussion of Key Presentations and Posters from the 2011 San Antonio ... and Fulvestrant as First-Line ... Trial to Evaluate ...
| PowerPoint PPT presentation | free to download
A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer Patients with Marginal Vitamin D Status PowerPoint PPT Presentation
A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer Patients with Marginal Vitamin D Status - A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast ...
A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast ...
| PowerPoint PPT presentation | free to download
Terapia Neoadiuvante Revisione delle evidenze scientifiche PowerPoint PPT Presentation
Terapia Neoadiuvante Revisione delle evidenze scientifiche - Title: Diapositiva 1 Author: Valentina Last modified by: Administrator Created Date: 11/18/2011 5:10:00 PM Document presentation format: Presentazione su schermo (4:3)
Title: Diapositiva 1 Author: Valentina Last modified by: Administrator Created Date: 11/18/2011 5:10:00 PM Document presentation format: Presentazione su schermo (4:3)
| PowerPoint PPT presentation | free to download
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer PowerPoint PPT Presentation
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer - A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in ...
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in ...
| PowerPoint PPT presentation | free to download
Analysis of Bevacizumab Therapy, Bisphosphonate Use, and Osteonecrosis of the Jaw in >3500 Patients Treated in Three Large Clinical Trials PowerPoint PPT Presentation
Analysis of Bevacizumab Therapy, Bisphosphonate Use, and Osteonecrosis of the Jaw in >3500 Patients Treated in Three Large Clinical Trials - Sporadic triple-negative breast ... + three patients with saline expanders and one with silicone implant; NS ... Reconstruction-related complications trended ...
Sporadic triple-negative breast ... + three patients with saline expanders and one with silicone implant; NS ... Reconstruction-related complications trended ...
| PowerPoint PPT presentation | free to download
Comparing the Prediction of Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score PowerPoint PPT Presentation
Comparing the Prediction of Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score - Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score
Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score
| PowerPoint PPT presentation | free to download
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer  PowerPoint PPT Presentation
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer - Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer First Efficacy Results from the LEA ...
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer First Efficacy Results from the LEA ...
| PowerPoint PPT presentation | free to download
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer PowerPoint PPT Presentation
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer - in Patients with HER2-Positive Advanced Breast Cancer ... 82% Neoadjuvant chemotherapy 18% 8%
in Patients with HER2-Positive Advanced Breast Cancer ... 82% Neoadjuvant chemotherapy 18% 8%
| PowerPoint PPT presentation | free to download
Shulman LN et al. PowerPoint PPT Presentation
Shulman LN et al. - Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
| PowerPoint PPT presentation | free to download
Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( PowerPoint PPT Presentation
Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( - Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( NeoSphere )
Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( NeoSphere )
| PowerPoint PPT presentation | free to download
Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study PowerPoint PPT Presentation
Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study - Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study
Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study
| PowerPoint PPT presentation | free to download
Kathy D. Miller, MD PowerPoint PPT Presentation
Kathy D. Miller, MD - Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...
Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...
| PowerPoint PPT presentation | free to download
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER PowerPoint PPT Presentation
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER - ... Drugs 2012 Ongoing trial of non HER-2 targeted agents Sharial et al, Ann Oncol 2012 PI3K pathway mTOR and PI3K inhibitors Phase I/II study X2107: ...
... Drugs 2012 Ongoing trial of non HER-2 targeted agents Sharial et al, Ann Oncol 2012 PI3K pathway mTOR and PI3K inhibitors Phase I/II study X2107: ...
| PowerPoint PPT presentation | free to view
Pathological Complete Response After Neoadjuvant Chemotherapy   Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial (An AGO GBG PowerPoint PPT Presentation
Pathological Complete Response After Neoadjuvant Chemotherapy Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial (An AGO GBG - Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
| PowerPoint PPT presentation | free to download
Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2  Early Stage Breast Cancer Patients PowerPoint PPT Presentation
Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2 Early Stage Breast Cancer Patients - Introduction Phase III US Oncology Research trial 9735 demonstrated that docetaxel/cyclophosphamide ... and there were no cases of clinical congestive heart failure.
Introduction Phase III US Oncology Research trial 9735 demonstrated that docetaxel/cyclophosphamide ... and there were no cases of clinical congestive heart failure.
| PowerPoint PPT presentation | free to download
Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy PowerPoint PPT Presentation
Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy - Title: Main Title Slide Always use Title Case on Slide Titles Author: Fernando G Rendina Last modified by: Aura Herrmann Created Date: 5/20/2009 1:19:04 AM
Title: Main Title Slide Always use Title Case on Slide Titles Author: Fernando G Rendina Last modified by: Aura Herrmann Created Date: 5/20/2009 1:19:04 AM
| PowerPoint PPT presentation | free to download
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF) Therapy  PowerPoint PPT Presentation
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF) Therapy - Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 3/16/2011 3:16:53 AM Document presentation format
Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 3/16/2011 3:16:53 AM Document presentation format
| PowerPoint PPT presentation | free to download
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1 Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer2 PowerPoint PPT Presentation
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1 Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer2 - Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1
| PowerPoint PPT presentation | free to download
Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase1  Osteonecrosis of the Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated with PowerPoint PPT Presentation
Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase1 Osteonecrosis of the Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated with - Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone ... breast cancer and bone metastasis reported an 18 percent ...
Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone ... breast cancer and bone metastasis reported an 18 percent ...
| PowerPoint PPT presentation | free to download
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44) PowerPoint PPT Presentation
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44) - Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
| PowerPoint PPT presentation | free to download
313 Patients with Breast Cancer During Pregnancy  PowerPoint PPT Presentation
313 Patients with Breast Cancer During Pregnancy - 313 Patients with Breast Cancer During Pregnancy Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03)
313 Patients with Breast Cancer During Pregnancy Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03)
| PowerPoint PPT presentation | free to download
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up PowerPoint PPT Presentation
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up - HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up
| PowerPoint PPT presentation | free to download
Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged =70 Years, from the Athena Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent (LR)/ Metastatic Breast Cancer (mBC) PowerPoint PPT Presentation
Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged =70 Years, from the Athena Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent (LR)/ Metastatic Breast Cancer (mBC) - ... / Metastatic Breast Cancer ... no concomitant endocrine therapy No uncontrolled ... Conclusions The addition of bevacizumab to neoadjuvant therapy for patients ...
... / Metastatic Breast Cancer ... no concomitant endocrine therapy No uncontrolled ... Conclusions The addition of bevacizumab to neoadjuvant therapy for patients ...
| PowerPoint PPT presentation | free to download
Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer1 Cell Cycle Effects of Iniparib plus Gemcitabine and Carboplatin in a Triple Negative Breast Cancer Cell Line2  Promoter CpG Methylation of BRCA1 PowerPoint PPT Presentation
Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer1 Cell Cycle Effects of Iniparib plus Gemcitabine and Carboplatin in a Triple Negative Breast Cancer Cell Line2 Promoter CpG Methylation of BRCA1 - Sensitivity to PARP inhibitors was assessed by: Cell proliferation assays (XTT ... BRCA1 promoter methylation may be assessed as a biomarker of response in current ...
Sensitivity to PARP inhibitors was assessed by: Cell proliferation assays (XTT ... BRCA1 promoter methylation may be assessed as a biomarker of response in current ...
| PowerPoint PPT presentation | free to download
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer1 The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; PowerPoint PPT Presentation
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer1 The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; - The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; Exploratory Analysis ...
The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; Exploratory Analysis ...
| PowerPoint PPT presentation | free to download
Essai AGO de phase III comparant une chimioth PowerPoint PPT Presentation
Essai AGO de phase III comparant une chimioth - Essai AGO de phase III comparant une chimioth rapie dose-dense s quentielle par ... (ETC) une chimioth rapie conventionnelle chez les patientes avec ...
Essai AGO de phase III comparant une chimioth rapie dose-dense s quentielle par ... (ETC) une chimioth rapie conventionnelle chez les patientes avec ...
| PowerPoint PPT presentation | free to view
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up PowerPoint PPT Presentation
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up - The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
| PowerPoint PPT presentation | free to download
Table ronde :  analyse de la litt PowerPoint PPT Presentation
Table ronde : analyse de la litt - Title: Table ronde : analyse de la litt rature Author: hardy Last modified by: PAVEAU V ronique Created Date: 3/28/2008 4:47:52 PM Document presentation format
Title: Table ronde : analyse de la litt rature Author: hardy Last modified by: PAVEAU V ronique Created Date: 3/28/2008 4:47:52 PM Document presentation format
| PowerPoint PPT presentation | free to download
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1  A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic PowerPoint PPT Presentation
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1 A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic - Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1
| PowerPoint PPT presentation | free to download
TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1 CALGB 40302: PowerPoint PPT Presentation
TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1 CALGB 40302: - Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1
Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1
| PowerPoint PPT presentation | free to download
Diapositiva 1 PowerPoint PPT Presentation
Diapositiva 1 - Roch H et al J Clin Oncol 2006. PACS-01: DFS in different subgroups (Forest plot analysis) ... Roch H et al J Clin Oncol 2006. ECTO Study. Gianni L, et al, ...
Roch H et al J Clin Oncol 2006. PACS-01: DFS in different subgroups (Forest plot analysis) ... Roch H et al J Clin Oncol 2006. ECTO Study. Gianni L, et al, ...
| PowerPoint PPT presentation | free to view
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial1 Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enzymes with Primary Endpoints PowerPoint PPT Presentation
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial1 Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enzymes with Primary Endpoints - Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
Title: Research To Practice Author: Fernando G Rendina Last modified by: Fernando Rendina Created Date: 5/20/2009 1:19:04 AM Document presentation format
| PowerPoint PPT presentation | free to download
Page of  


PowerPlugs
PowerPlugs
View by Category
Presentations
  • Photo Slideshows
  • Presentations (free-to-view)
    • Concepts & Trends
    • Entertainment
    • Fashion & Beauty
    • Government & Politics
    • How To, Education & Training
    • Medicine, Science & Technology
    • Other
    • Pets & Animals
    • Products & Services
    • Religious & Philosophical
    • Travel & Places
  • Presentations (pay-to-view)
Products Sold on our sister site CrystalGraphics.com
  • Ultimate Combo for PPT
  • PowerPoint Templates
  • Charts & Diagrams for PPT
  • 3D Character Slides
  • Background Videos for PPT
  • More Products for PPT
PowerPlugs
PowerPlugs
CrystalGraphics
Home About Us Terms and Conditions Privacy Policy Contact Us Send Us Feedback
Copyright 2021 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
sabcs — Search results on PowerShow.com
Loading...